Wave Life Sciences .(WVE) - 2024 Q4 - Annual Results

Exhibit 99.1 Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose cohort Multi-dosing ongoing in 200 mg cohort of RestorAATion-2 clinical trial of WVE-006 in AATD with data expected in 2025; second single dose cohort initiated at 400 mg Recent Business Highlights and Expected Milestones GalNAc-siRNA Programs Obesity • W ...